R&D | April 13, 2026
Merck India, MAHE launch catalyst program to build future R&D talent pipeline
MoU aims to strengthen academia-industry collaboration in healthcare research and innovation
MoU aims to strengthen academia-industry collaboration in healthcare research and innovation
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
Capital infusion to accelerate Earendil’s R&D platform
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Subscribe To Our Newsletter & Stay Updated
